• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IJID Reg . Cost-effectiveness of routine influenza vaccination program for individuals aged 65 years and older in Japan: Substituting standard-dose

tetano

Editor, Senior Moderator
IJID Reg


. 2026 Feb 13:18:100858.
doi: 10.1016/j.ijregi.2026.100858. eCollection 2026 Mar.
Cost-effectiveness of routine influenza vaccination program for individuals aged 65 years and older in Japan: Substituting standard-dose inactivated vaccine with high-dose inactivated vaccine

Shu-Ling Hoshi[SUP] 1 [/SUP], Xerxes Seposo[SUP] 2 [/SUP], Masahide Kondo[SUP] 1 [/SUP]


Affiliations
Abstract

Objectives: We evaluated cost-effectiveness of influenza immunization programs for protection of Japanese elderly (aged ≥65 years) from influenza-related diseases by comparing high-dose inactivated influenza vaccine (HD-IIV3) to standard vaccines (SD-IIV3).
Methods: Incremental cost-effectiveness ratio (ICER) from payers' perspective was calculated. Variables used in the model were either calculated or extracted from literature. Quality-adjusted life years (QALYs) was used as measure of effectiveness. Cost per dose of HD vaccine was assumed to be four times of SD (JPY 1500/US$ 10).
Results: In comparison to SD, HD gained more QALYs and reduced disease treatment costs, but these reduced costs did not offset vaccination cost. ICER for those aged ≥65 years was JPY 7,352,458/ US$ 49,016 per QALY, higher than the willingness-to-pay (WTP) threshold of JPY 5,000,000/US$ 33,333 per QALY. While ICER was JPY 50,477,31/US$ 33,652 for those aged ≥75 years. One-way sensitivity analysis revealed that relative vaccine effect against laboratory-confirmed influenza of HD to SD influenced the ICER the most. Monte Carlo simulations revealed that the probability of an ICER below WTP threshold was 20.9%.
Conclusions: For a WTP of JPY 5,000,000/US$ 33,333 per QALY gained, if the price of HD was four times the current vaccine, the seasonal HD-IIV3 vaccination program was not cost-effective for those aged ≥65 years, while was cost-effective for those aged ≥75 years.

Keywords: Decision-tree model; Incremental cost-effectiveness ratio (ICER); Monte Carlo simulations; Quality-adjusted life year (QALY); Willingness-to-pay (WTP).

 
Back
Top Bottom